BRPI0811142A8 - prevenção e tratamento de condições oculares associadas a complementos - Google Patents

prevenção e tratamento de condições oculares associadas a complementos

Info

Publication number
BRPI0811142A8
BRPI0811142A8 BRPI0811142A BRPI0811142A BRPI0811142A8 BR PI0811142 A8 BRPI0811142 A8 BR PI0811142A8 BR PI0811142 A BRPI0811142 A BR PI0811142A BR PI0811142 A BRPI0811142 A BR PI0811142A BR PI0811142 A8 BRPI0811142 A8 BR PI0811142A8
Authority
BR
Brazil
Prior art keywords
eye conditions
prevention
treatment
supplements
conditions associated
Prior art date
Application number
BRPI0811142A
Other languages
English (en)
Portuguese (pt)
Inventor
Wiesmann Christian
Yin Jianping
Katschke Kenneth Jr
Van Lookeren Campagne Menno
Steffek Micah
Hass Philip
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39638868&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0811142(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BRPI0811142A2 publication Critical patent/BRPI0811142A2/pt
Publication of BRPI0811142A8 publication Critical patent/BRPI0811142A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
BRPI0811142A 2007-05-23 2008-05-22 prevenção e tratamento de condições oculares associadas a complementos BRPI0811142A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93979107P 2007-05-23 2007-05-23
PCT/US2008/064526 WO2008147883A1 (en) 2007-05-23 2008-05-22 Prevention and treatment of complement-associated eye conditions

Publications (2)

Publication Number Publication Date
BRPI0811142A2 BRPI0811142A2 (pt) 2014-12-23
BRPI0811142A8 true BRPI0811142A8 (pt) 2018-12-18

Family

ID=39638868

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0811142A BRPI0811142A8 (pt) 2007-05-23 2008-05-22 prevenção e tratamento de condições oculares associadas a complementos

Country Status (28)

Country Link
US (6) US8007791B2 (cg-RX-API-DMAC7.html)
EP (1) EP2152755B1 (cg-RX-API-DMAC7.html)
JP (4) JP5416695B2 (cg-RX-API-DMAC7.html)
KR (1) KR101540126B1 (cg-RX-API-DMAC7.html)
CN (3) CN107096029B (cg-RX-API-DMAC7.html)
AR (1) AR066660A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008256835B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0811142A8 (cg-RX-API-DMAC7.html)
CA (1) CA2683498A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008001498A1 (cg-RX-API-DMAC7.html)
CY (1) CY1116062T1 (cg-RX-API-DMAC7.html)
DK (1) DK2152755T3 (cg-RX-API-DMAC7.html)
ES (1) ES2533242T3 (cg-RX-API-DMAC7.html)
HK (1) HK1207327A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20150281T1 (cg-RX-API-DMAC7.html)
IL (2) IL201476A (cg-RX-API-DMAC7.html)
MX (1) MX2009012422A (cg-RX-API-DMAC7.html)
PE (1) PE20090294A1 (cg-RX-API-DMAC7.html)
PH (1) PH12013500992B1 (cg-RX-API-DMAC7.html)
PL (1) PL2152755T3 (cg-RX-API-DMAC7.html)
PT (1) PT2152755E (cg-RX-API-DMAC7.html)
RS (1) RS53901B1 (cg-RX-API-DMAC7.html)
RU (2) RU2522976C2 (cg-RX-API-DMAC7.html)
SG (1) SG10201401404RA (cg-RX-API-DMAC7.html)
SI (1) SI2152755T1 (cg-RX-API-DMAC7.html)
TW (2) TW201417829A (cg-RX-API-DMAC7.html)
WO (1) WO2008147883A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200907028B (cg-RX-API-DMAC7.html)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2316446T3 (es) * 2000-04-29 2009-04-16 University Of Iowa Research Foundation Diagnostico y terapeutica para trastornos relacionados con la degeneracion macular.
NZ567483A (en) 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
JP2010508819A (ja) 2006-11-02 2010-03-25 ジェネンテック インコーポレイテッド ヒト化抗ｄ因子抗体
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
CA2735779A1 (en) * 2008-09-02 2010-03-11 Matthew Burger Bicyclic kinase inhibitors
CA3045436C (en) 2009-01-29 2025-10-07 Forsight Vision4, Inc. ADMINISTRATION OF A MEDICATION IN THE POSTERIOR SEGMENT
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US9309325B2 (en) 2009-05-07 2016-04-12 The Regents Of The University Of California Antibodies and methods of use thereof
US20110165648A1 (en) 2009-11-04 2011-07-07 Menno Van Lookeren Campagne Co-crystal structure of factor D and anti-factor D antibody
US9492315B2 (en) * 2010-08-05 2016-11-15 Forsight Vision4, Inc. Implantable therapeutic device
MX348025B (es) 2010-11-01 2017-05-24 Genentech Inc * Prediccion del paso a degeneracion macular avanzada relacionada con la edad utilizando una puntuacion poligenica.
PH12013501436A1 (en) 2011-01-04 2013-09-09 Novartis Ag Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
US20120189633A1 (en) 2011-01-26 2012-07-26 Kolltan Pharmaceuticals, Inc. Anti-kit antibodies and uses thereof
CN104603126B (zh) 2012-06-28 2017-05-31 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
JP6214647B2 (ja) 2012-06-28 2017-10-18 ノバルティス アーゲー 補体経路モジュレーターおよびその使用
US9815819B2 (en) 2012-06-28 2017-11-14 Novartis Ag Complement pathway modulators and uses thereof
JP6155332B2 (ja) 2012-06-28 2017-06-28 ノバルティス アーゲー ピロリジン誘導体、および補体経路調節因子としてのその使用
CN104379579B (zh) 2012-06-28 2017-03-08 诺华股份有限公司 吡咯烷衍生物及其作为补体途径调节剂的用途
CN104684910B (zh) 2012-07-12 2016-10-12 诺华股份有限公司 补体途经调节剂及其用途
DK2877493T3 (en) 2012-07-25 2018-06-14 Celldex Therapeutics Inc ANTI-KIT ANTIBODIES AND APPLICATIONS THEREOF
WO2014120555A1 (en) 2013-01-31 2014-08-07 The Regents Of The University Of California Antibodies specific for urokinase-type plasminogen activator and methods of use thereof
US9526654B2 (en) 2013-03-28 2016-12-27 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
KR20180021234A (ko) 2013-08-12 2018-02-28 제넨테크, 인크. 보체-연관 상태의 치료를 위한 조성물 및 방법
WO2015054298A1 (en) * 2013-10-07 2015-04-16 Massachusetts Eye And Ear Infirmary Methods of preventing or reducing photoreceptor cell death
WO2015061658A1 (en) * 2013-10-25 2015-04-30 Children's Medical Center Corporation Methods of treating or preventing vascular diseases of the retina
JP2017515811A (ja) * 2014-05-01 2017-06-15 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体変異体及びその使用法
CN113908269A (zh) 2014-05-23 2022-01-11 塞尔德克斯医疗公司 嗜酸性粒细胞或肥大细胞相关病症的治疗
RS66924B1 (sr) * 2015-09-23 2025-07-31 Sangamo Therapeutics Inc Htt represori i njihova upotreba
CN108289951A (zh) * 2015-10-30 2018-07-17 豪夫迈·罗氏有限公司 抗-因子d抗体和缀合物
EP3368578B1 (en) 2015-10-30 2021-03-17 H. Hoffnabb-La Roche Ag Anti-htra1 antibodies and methods of use thereof
CN108472382A (zh) * 2015-10-30 2018-08-31 豪夫迈·罗氏有限公司 抗-因子d抗体变体缀合物及其用途
HK1257425A1 (zh) 2015-10-30 2019-10-18 豪夫迈‧罗氏有限公司 测量因子d活性和因子d抑制剂效力的方法
SI3394089T1 (sl) * 2015-12-23 2021-12-31 eleva GmbH Polipeptidi za inhibiranje aktivacije komplementa
EP3405577B8 (en) 2016-01-20 2023-02-15 396419 B.C. Ltd. Compositions and methods for inhibiting factor d
WO2018136827A1 (en) 2017-01-20 2018-07-26 Vitrisa Therapeutics, Inc. Stem-loop compositions and methods for inhibiting factor d
IL268601B2 (en) 2017-02-10 2024-07-01 Univ Pennsylvania Anti-factor d antibodies and uses thereof
CN109632924B (zh) * 2018-12-17 2022-02-08 上海市第一人民医院 人黄斑新生血管性疾病的血浆脂质标记物及其应用
WO2021009778A2 (en) * 2019-07-18 2021-01-21 Pandorum Technologies Private Limited Methods for culturing mesenchymal stem cells, products thereof, and applications thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6620915B2 (en) * 1993-12-23 2003-09-16 Icos Corporation Monoclonal antibodies specific for integrin α-d subunit
WO2002008284A2 (en) 2000-07-20 2002-01-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2001036432A2 (en) 1999-11-19 2001-05-25 Human Genome Sciences, Inc. 18 human secreted proteins
US20050197285A1 (en) * 1997-03-07 2005-09-08 Rosen Craig A. Human secreted proteins
US6472520B2 (en) * 1997-03-21 2002-10-29 The Trustees Of Columbia University In The City Of New York Rat PEG-3 promoter
US6410708B1 (en) * 1997-11-21 2002-06-25 Genentech, Inc. Nucleic acids encoding A-33 related antigen polypeptides
US7192589B2 (en) * 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ES2316175T3 (es) 1997-11-21 2009-04-01 Genentech, Inc. Antigenos especificos de plaquetas y sus usos farmacologicos.
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
US7282565B2 (en) * 1998-03-20 2007-10-16 Genentech, Inc. PRO362 polypeptides
US7419663B2 (en) * 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
AU2577799A (en) * 1998-02-09 1999-08-23 Human Genome Sciences, Inc. 45 human secreted proteins
US6956107B2 (en) 1998-02-20 2005-10-18 Tanox, Inc. Inhibitors of complement activation
CA2321140C (en) * 1998-02-20 2015-04-07 Tanox, Inc. Inhibitors of complement activation
NZ507435A (en) 1998-03-10 2003-12-19 Genentech Inc Novel polypeptides and nucleic acids with homology to cornichon
JP2002523089A (ja) 1998-08-27 2002-07-30 インサイト・ファーマスーティカルズ・インコーポレイテッド タンパク質輸送関連分子
CA2348757A1 (en) 1998-12-16 2000-06-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
ES2259247T3 (es) * 1998-12-21 2006-09-16 Ludwig Institute For Cancer Research Anticuerpos frente a vegf-d truncado y sus usos.
ATE353339T1 (de) 1998-12-22 2007-02-15 Genentech Inc Verfahren und zusammensetzung zur hemmung des neoplastischen zellwachstums
EP1220905A2 (en) 1999-03-08 2002-07-10 Genentech Inc. Composition and methods for the treatment of immune related diseases
HU229376B1 (en) 1999-03-11 2013-11-28 Serono Lab Vascular adhesion molecules and modulation of their function
US6642353B1 (en) * 1999-03-17 2003-11-04 Chugai Seiyaku Kabushiki Kaisha Peptide ligands for the erythropoietin receptor
AU2883900A (en) 1999-07-07 2001-01-30 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
AU1423601A (en) 1999-11-02 2001-05-30 Uliyanovsky Gosudarstvenny Tekhnichesky Universitet Method for cleaning liquids of ferromagnetic particles and device for the implementation thereof
CA2494705A1 (en) 1999-12-01 2001-06-07 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2412211A1 (en) 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
WO2004022594A2 (en) 2002-09-06 2004-03-18 Cytos Biotechnology Ag Immune modulatory compounds and methods
RU2232991C1 (ru) * 2003-04-09 2004-07-20 Государственное учреждение "Московский научно-исследовательский институт эпидемиологии и микробиологии им. Г.Н. Габричевского" Способ определения функциональной активности фактора d комплемента человека
WO2006071856A2 (en) 2004-12-23 2006-07-06 Glycofi, Inc. Immunoglobulins comprising predominantly a man5glcnac2 glycoform
NZ567483A (en) * 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
JP2010508819A (ja) * 2006-11-02 2010-03-25 ジェネンテック インコーポレイテッド ヒト化抗ｄ因子抗体
AR066660A1 (es) * 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
JP4349447B2 (ja) 2007-07-19 2009-10-21 トヨタ自動車株式会社 インバータ制御装置および車両

Also Published As

Publication number Publication date
US20160272726A1 (en) 2016-09-22
KR20100033973A (ko) 2010-03-31
MX2009012422A (es) 2009-12-04
TW201417829A (zh) 2014-05-16
EP2152755A1 (en) 2010-02-17
CN101754980B (zh) 2014-10-29
SG10201401404RA (en) 2014-08-28
US20130302333A1 (en) 2013-11-14
AU2008256835A1 (en) 2008-12-04
JP2014087346A (ja) 2014-05-15
PL2152755T3 (pl) 2015-06-30
TWI419704B (zh) 2013-12-21
PH12013500992A1 (en) 2016-01-25
PT2152755E (pt) 2015-04-01
KR101540126B1 (ko) 2015-07-28
US8268310B2 (en) 2012-09-18
CN101754980A (zh) 2010-06-23
EP2152755B1 (en) 2014-12-31
CL2008001498A1 (es) 2009-06-12
JP2017197577A (ja) 2017-11-02
US8007791B2 (en) 2011-08-30
CN107096029A (zh) 2017-08-29
US8497094B2 (en) 2013-07-30
IL201476A0 (en) 2010-05-31
IL201476A (en) 2016-11-30
RU2009147744A (ru) 2011-06-27
PE20090294A1 (es) 2009-03-27
AR066660A1 (es) 2009-09-02
JP2010528047A (ja) 2010-08-19
CY1116062T1 (el) 2017-02-08
US20180079826A1 (en) 2018-03-22
RS53901B1 (sr) 2015-08-31
TW200904471A (en) 2009-02-01
DK2152755T3 (en) 2015-03-02
ES2533242T3 (es) 2015-04-08
HK1207327A1 (en) 2016-01-29
CA2683498A1 (en) 2008-12-04
HRP20150281T1 (hr) 2015-04-10
CN107096029B (zh) 2021-02-26
CN104367999A (zh) 2015-02-25
HK1139161A1 (en) 2010-09-10
US20130052685A1 (en) 2013-02-28
IL248552A0 (en) 2016-12-29
RU2014113046A (ru) 2015-10-10
RU2522976C2 (ru) 2014-07-20
WO2008147883A8 (en) 2013-05-23
US20090181017A1 (en) 2009-07-16
ZA200907028B (en) 2010-12-29
JP2016145205A (ja) 2016-08-12
JP5416695B2 (ja) 2014-02-12
WO2008147883A1 (en) 2008-12-04
US20110282034A1 (en) 2011-11-17
PH12013500992B1 (en) 2018-12-14
SI2152755T1 (sl) 2015-05-29
AU2008256835B2 (en) 2013-08-01
BRPI0811142A2 (pt) 2014-12-23

Similar Documents

Publication Publication Date Title
BRPI0811142A8 (pt) prevenção e tratamento de condições oculares associadas a complementos
CL2017001191A1 (es) Compuestos derivados de carbamoilpiridona policíclicos; composición farmacéutica que los comprende; y su uso para el tratamiento de una infección de vih en un humano que tiene o se encuentra en riesgo de tener la infección.
EA201590053A1 (ru) Модуляторы пути системы комплемента и их применение
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
CL2008003120A1 (es) Compuestos derivados de fenilalquil-, fenilalquenil-, fenilalquinil- amina, feniltioalquilamina, fenilaminoalquilamina, fenilalcoxiamina y fenilalquilguanidina; composicion farmaceutica; y uso de los compuestos para tratar un trastorno o enfermedad oftalmologica tal como retinopatia, maculopatia, retinitis pigmentosa, uveitis, entre otras.
MX346224B (es) Composiciones y metodos para el tratamiento de inflamacion cronica y enfermedades inflamatorias.
CL2014000171A1 (es) Compuestos derivados de tetrahidropirido-piridina y tetrahidropirido-pirimidina, moduladores de receptores de c5a; composicion farmaceutica que los comprende; combinacion farmaceutica; uso en el tratamiento de degeneracion macular relacionada con la edad, retinopatia diabetica, esclerosis multiple, ave, enfermedad de parkinson, enfermedad de crohn, entre otras.
UY36465A (es) Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico
UY32673A (es) Nuevas pirimidinas, composiciones farmaceuticas que las contienen, procedimientos de preparaciones y su aplicacion como medicamentos
MX377410B (es) Antagonistas de receptores de integrina y sus metodos de uso.
SG10201804552WA (en) Nanoparticle compositions, formulations thereof, and uses therefor
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
MX2016015248A (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
BR112014015568A8 (pt) compostos carbamato de fenila para uso em prevenção ou tratamento de epilepsia
BR112013030554A2 (pt) forma cristalina de ciclosporina a, métodos de preparação e métodos para uso da mesma
ECSP11010956A (es) Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos
ECSP17026748A (es) Diamino-quinoleína 2,4 sustituida como nuevos agentes anticancerígenos
BR112014005025A2 (pt) composição farmacêutica para uso no tratamento de uma doença neurodegenerativa
ES2429422R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
BRPI0820343A2 (pt) Anticorpos de antifator b e seus usos
MX367926B (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
BR112014026817A2 (pt) derivados do pantotenato para o tratamento de transtornos neurológicos
AR079000A1 (es) Terapia anticancerosa dirigida a celulas madre cancerosas resistentes a las drogas
EA201591415A1 (ru) Фармацевтические композиции, включающие многокомпонентные кристаллические частицы, подходящие для применения в ингаляционной терапии
BR112013025610A2 (pt) uso de um metapneumovírus aviário vivo, e, composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]